Quantitative Expression of Toll-Like Receptors TLR-7 and TLR-9 on Peripheral Blood Mononuclear Cells in Leukemias

Morsi, Mona; Gharabawy, M. M.; Hamed, Nahla A M; Sawy, Mohamed M. El; Seada, Noha M. Abou; Hashad, Rola

doi:10.14740/jh249w

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the TLR9 was ranging from 0.10 to 2.40% with a median of 1.30%. This finding coinciding with that reported by Morsi et al [16], where they found a range of (0.941-1.571%) with a mean of 1.35% among 15 AML patients.…”

Section: Discussionsupporting

confidence: 92%

Toll-like receptor 9 negatively related to clinical outcome of AML patients

Al-Kahiry

Dammag

Abdelsalam

et al. 2020

J Egypt Natl Canc Inst

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) can modulate toll-like receptor-9 (TLR9) expression and activation. This study was conducted to elucidate the expression of TLR9 in AML patients and its relation to the prognosis of the disease. Results: The study included 40 newly diagnosed AML patients managed in the hospital in addition to 20 sex and age matched normal volunteers as control. TLR9 expression assay was conducted on peripheral blood samples of AML cases before the start of treatment as well as the controls by immunophenotyping. TLR9 expression was ranging from 0.10 to 2.40% in AML patients with higher expression among the control, ranging from 0.94 to 8.25%. The median TLR9 expression in AML patients was significantly lower with advanced cytogenetic risk score. It is not significantly differing in relation to patients' sex, age group, and FAB type of AML. However, significant lower median expression was found in relation to clinical outcome. TLR9 expression ≤ 1% showed lower median overall survival time when compared to those with > 1% expression. Conclusion: This study concluded that AML patients express TLR9 in leukemic cells with very low percentage. This expression was negatively related to the clinical outcome.

show abstract

Section: Discussionsupporting

confidence: 92%

Toll-like receptor 9 negatively related to clinical outcome of AML patients

Al-Kahiry

Dammag

Abdelsalam

et al. 2020

J Egypt Natl Canc Inst

View full text Add to dashboard Cite

show abstract

“…In addition, in most studies, TLR6 C > T rs5743810 is associated with infectious diseases like tuberculosis in the African population and the induction of resistance to asthma in children 35 . In CLL, high TLR6 expression was observed in cells of the patients 36 , but it is still not clear what the role of this polymorphism is in leukemia.…”

Section: Discussionmentioning

confidence: 99%

“…In AML, the [C] allele of TLR9 C > T rs187084 and [T] TLR9 C > T rs5743836 are associated with disease development, as is the TT genotype of the TLR9 C > T rs5743836 polymorphism with relapse episodes 40 . Additionally, the TLR9 gene is significantly expressed in chronic lymphocytic leukemia cells 36 .…”

Section: Discussionmentioning

confidence: 99%

Association of Toll-like receptors polymorphisms with the risk of acute lymphoblastic leukemia in the Brazilian Amazon

Xabregas

Hanna

Souza

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children in childhood. Single-nucleotide polymorphism (SNPs) in key molecules of the immune system, such as Toll-like receptors (TLRs) and CD14 molecules, are associated with the development of several diseases. However, their role in ALL is unknown. A case–control study was performed with 152 ALL patients and 187 healthy individuals to investigate the role of SNPs in TLRs and the CD14 gene in ALL. In this study, TLR6 C > T rs5743810 [OR: 3.20, 95% CI: 1.11–9.17, p = 0.003) and TLR9 C > T rs187084 (OR: 2.29, 95% CI: 1.23–4.26, p = 0.000) seems to be a risk for development of ALL. In addition, the TLR1 T > G rs5743618 and TLR6 C > T rs5743810 polymorphisms with protection against death (OR: 0.17, 95% IC: 0.04–0.79, p = 0.008; OR: 0.48, 95% IC: 0.24–0.94, p = 0.031, respectively). Our results show that SNPs in TLRs genes may be involved in the pathogenesis of ALL and may influence clinical prognosis; however, further studies are necessary to elucidate the role of TLR1, TLR4, TLR5, TLR6, TLR9 and CD14 polymorphisms in this disease.

show abstract

“…In other hematological cancers, such as acute myeloid leukemia (AML), the mRNA expression levels of TLR2 and TLR4, but not of TLR9, were increased, contrary to what was observed in ALL [ 37 ], and expression of TLR7 and 9 was decreased in chronic myeloid leukemia (CML) [ 38 ]. In chronic lymphocytic leukemia (CLL), there was an increase in the expression of TLRs 1, 2, 6, 7, 9, and 10 [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

NK Cell Subpopulation Is Altered and the Expression of TLR1 and TLR9 Is Decreased in Patients with Acute Lymphoblastic Leukemia

Sánchez-Herrera

Contreras-Ramos

Jiménez‐Hernández

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

NK cells represent a heterogeneous subpopulation of lymphocytes of the innate immune system, which possess powerful antitumor activity. NK cells exhibit their function through a complex collection of receptors that act synergistically to recognize, regulate, or amplify the immune response. TLRs allow cells to detect PAMPs, MAMPs, or DAMPs, which are essential for the initiation of the immune response. Studies on the different subpopulations of NK cells and their expression profile of innate immune receptors in hematological cancers are limited. In this study, the specific subpopulations of NK cells in pediatric patients with acute lymphoblastic leukemia (ALL) and the repertoire and level of expression of TLRs in cytotoxic NK cells were assessed. The results suggested that pediatric patients with ALL exhibited a significant decrease in NK cells in peripheral blood and bone marrow, in addition to alterations in the distribution of the subpopulations of cells. Regulatory and cytotoxic NK cells were diminished, whereas dysfunctional phenotype was considerably increased. Cytotoxic NK cells from children with ALL expressed all 10 TLRs, and expression of TLR1 and TLR9 was decreased compared with the controls. Interestingly, cytotoxic NK cells exhibited a higher expression of TLR1 in the bone marrow than in the peripheral blood of patients with ALL. The present study is the first to show that TLR10 was expressed in the cytotoxic NK cells and the first to assess the profile and levels of the 10 known TLRs in cytotoxic NK cells from patients with ALL. The alterations in expression levels and cellular distribution may be involved in the immune response.

show abstract

Quantitative Expression of Toll-Like Receptors TLR-7 and TLR-9 on Peripheral Blood Mononuclear Cells in Leukemias

Cited by 4 publications

References 31 publications

Toll-like receptor 9 negatively related to clinical outcome of AML patients

Toll-like receptor 9 negatively related to clinical outcome of AML patients

Association of Toll-like receptors polymorphisms with the risk of acute lymphoblastic leukemia in the Brazilian Amazon

NK Cell Subpopulation Is Altered and the Expression of TLR1 and TLR9 Is Decreased in Patients with Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About